Navigation Links
Stemedica Achieves Major Milestone - Company Receives License to Manufacture Clinical Grade Stem Cells
Date:9/1/2009

custom manufacture for select companies. These dynamic capabilities give us a significant point of advantage in the marketplace." said Roger Howe, PhD, Executive Chairman for Stemedica.

Stemedica has dedicated significant financial and human resources over the past four years in preparation for securing this license. The government's rigorous inspection and approval process has included: a comprehensive, in-depth audit of Stemedica's manufacturing process and procedures; examination of Stemedica's Quality Systems; interviews with facility management; and an onsite inspection of the facility.

"We're very proud of the hard work, dedication and professionalism of the team that has made this possible." stated Maynard Howe, PhD, Stemedica's Vice Chairman and Chief Executive Officer. "Their experience and expertise has been instrumental in assuring that our facility meets regulatory compliance requirements. With the approval and licensing process behind us we can now focus our efforts on manufacturing the highest quality stem cell products."

About Stemedica Cell Technologies
Stemedica Cell Technologies, Inc. (www.stemedica.com) is a specialty biopharmaceutical company that is committed to the development and manufacturing of best-in-class adult stem cells and stem cell factors for use by approved research institutions and hospitals for pre-clinical and human clinical trials. The company has currently filed a pre-IND request with the FDA in preparation of IND submissions for stroke and wound repair. Stemedica is headquartered in San Diego, California.

Media Contact for Stemedica: Dave McGuigan at dmcguigan (at) stemedica.com

Read t
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

0

GOOD

Page: 1 2 3

Related biology technology :

1. Stemedica Selected By World Stem Cell Summit To Present Scientific Discoveries
2. Stemedica Requests Pre-IND Meeting With FDA
3. Stemedica Signs Scientific Advisory Board Agreement with Leading Pediatric Burn & Wound Care Researcher
4. Renowned Stem Cell Researcher Files Study Results With Stemedica
5. CIRM Completes Briefing Visit to Stemedica Cell Technologies
6. Stemedica Announces the Appointment of Dr. Michael Bayer as Director, Medical Services
7. BioNeutrals Ygiene(TM) Hospital Grade Achieves a 100% Total Kill (Pass) Against the Life Threatening Clostridium Difficile (C.diff) Spores in Independent EPA Required Protocol Testing.
8. BioNeutrals Ygiene(TM) Hospital Grade Achieves World Class Independent Test Results in Killing Life Threatening Spores/Organisms
9. Environmental Tectonics Corporations BioMedical Division Achieves Foreign Manufacturer Accreditation in Japan
10. Healthy Advice Networks Achieves Strong Growth Despite Challenging Economy
11. Pepscan Achieves a Breakthrough With CLIPS Immunogen Technology: Synthetic Peptide Antigen is Able to Induce Fully Functional Antibodies Against a Formerly Intractable GPCR Target CXCR7
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Stemedica Achieves Major Milestone - Company Receives License to Manufacture Clinical Grade Stem Cells 
Stemedica Achieves Major Milestone - Company Receives License to Manufacture Clinical Grade Stem Cells
(Date:12/14/2009)... THOUSAND OAKS, Calif., Dec. 14 Array ... Inc.(Nasdaq: AMGN ) today announced that they ... rights to Array,s small-molecule glucokinase activator program, including ... clinical trial in patients with Type 2 diabetes. ... agreement, Array will receive an upfront payment of ...
(Date:12/14/2009)... The third edition of ... published by the Infusion Nurses Society (INS), ... extravasation.(1) Anthracyclines are a group of chemotherapy ... have been used in the treatment of various ... ,, According to the INS publication: "In ...
(Date:12/14/2009)... WALTHAM, Mass., Dec. 14 Decision Resources, ... firms for pharmaceutical and healthcare issues, finds that, ... the atrial fibrillation drug market will increase more ... $6.1 billion in 2018 in the United States, ... Japan. ,, The new Pharmacor report entitled ...
(Date:12/11/2009)... 11 Dendreon Corporation (Nasdaq: DNDN ... previously announced public offering have exercised in full ... of common stock at the public offering price ... the option increases the size of the offering ... stock. Dendreon expects to receive net proceeds ...
Breaking Biology Technology:Array BioPharma and Amgen Partner in Type 2 Diabetes 2Array BioPharma and Amgen Partner in Type 2 Diabetes 3Array BioPharma and Amgen Partner in Type 2 Diabetes 4Array BioPharma and Amgen Partner in Type 2 Diabetes 5Array BioPharma and Amgen Partner in Type 2 Diabetes 6Array BioPharma and Amgen Partner in Type 2 Diabetes 7Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 2Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 3Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 4Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 5The Atrial Fibrillation Drug Market Will Increase More Than Sevenfold, from $790 Million in 2008 to $6.1 Billion in 2018 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 3
... Million in 3Q08 -- ... $16.5 Million -- -- ... NEW YORK, Nov. 10 /Xinhua-PRNewswire-FirstCall/ -- American Oriental,Bioengineering, Inc. ... through the development, manufacture and commercialization,of a broad range of ...
... AVIV, Israel, November 10 InspireMD, developers of,the ... MGuard(TM),was successfully implanted in a complex lesion in ... was performed by Dr. Dariusz Dudek and was ... New Approach to Treating Thrombus Containing Lesions (ACS, ...
... ... ... pharmaceuticals company, today announced,that it had successfully closed a third ... developing its unique,CriticalMix delivery technology and matching pipeline of candidate ...
Other Biology Technology:American Oriental Bioengineering Reports Third Quarter 2008 Financial Results 2American Oriental Bioengineering Reports Third Quarter 2008 Financial Results 3American Oriental Bioengineering Reports Third Quarter 2008 Financial Results 4American Oriental Bioengineering Reports Third Quarter 2008 Financial Results 5American Oriental Bioengineering Reports Third Quarter 2008 Financial Results 6American Oriental Bioengineering Reports Third Quarter 2008 Financial Results 7American Oriental Bioengineering Reports Third Quarter 2008 Financial Results 8MGuard(TM), InspireMD's Novel Coronary Stent System, was Celebrated by World Leading Interventional Cardiologists at the Transcatheter Cardiovascular Therapeutics (TCT) in Washington DC, USA, October 12-17 2008 2MGuard(TM), InspireMD's Novel Coronary Stent System, was Celebrated by World Leading Interventional Cardiologists at the Transcatheter Cardiovascular Therapeutics (TCT) in Washington DC, USA, October 12-17 2008 3MGuard(TM), InspireMD's Novel Coronary Stent System, was Celebrated by World Leading Interventional Cardiologists at the Transcatheter Cardiovascular Therapeutics (TCT) in Washington DC, USA, October 12-17 2008 4Critical Pharmaceuticals Raise GBP650K 2Critical Pharmaceuticals Raise GBP650K 3
(Date:12/14/2009)... HOUSTON -- (Dec. 14, 2009) -- Researchers at Rice ... a single nanoparticle that can be tracked in real ... cells, tags them with a fluorescent dye and kills ... the first examples from a growing field called "theranostics" ... treat diseases in a single procedure. , The research ...
(Date:12/14/2009)... as a clean-burning, renewable fuel that could help wean ... caused by ozone, compared with gasoline, especially in winter, ... , Ozone production from both gasoline and E85, ... percent ethanol, is greater in warm sunny weather than ... because heat and sunlight contribute to ozone formation. But ...
(Date:12/14/2009)... Engineering Society (BMES) have founded a new journal ... CVET is a forum for research on ... The first issue of the new quarterly journal will ... publications at Springer, Annals of Biomedical Engineering ... Cardiovascular Engineering and Technology will present a wide ...
Breaking Biology News(10 mins):Tracking new cancer-killing particles with MRI 2Ethanol-powered vehicles generate more ozone than gas-powered ones 2Ethanol-powered vehicles generate more ozone than gas-powered ones 3Biomedical Engineering Society's new journal to be published by Springer 2Idenix Pharmaceuticals Successfully Completes Proof of Concept Study of IDX184 for the Treatment of Hepatitis C Virus 28HCV 29 4752 1Idenix Pharmaceuticals Successfully Completes Proof of Concept Study of IDX184 for the Treatment of Hepatitis C Virus 28HCV 29 4752 2Idenix Pharmaceuticals Successfully Completes Proof of Concept Study of IDX184 for the Treatment of Hepatitis C Virus 28HCV 29 4752 3Idenix Pharmaceuticals Successfully Completes Proof of Concept Study of IDX184 for the Treatment of Hepatitis C Virus 28HCV 29 4752 4Idenix Pharmaceuticals Successfully Completes Proof of Concept Study of IDX184 for the Treatment of Hepatitis C Virus 28HCV 29 4752 5Prospective Clinical Advantages of Trabecular Metal 28TM 29 Technology Highlighted in Comparative Study 4750 1Prospective Clinical Advantages of Trabecular Metal 28TM 29 Technology Highlighted in Comparative Study 4750 2Prospective Clinical Advantages of Trabecular Metal 28TM 29 Technology Highlighted in Comparative Study 4750 3Prospective Clinical Advantages of Trabecular Metal 28TM 29 Technology Highlighted in Comparative Study 4750 4Prospective Clinical Advantages of Trabecular Metal 28TM 29 Technology Highlighted in Comparative Study 4750 5Vein Condition May Mask Serious Clot Disorder 52152 1Vein Condition May Mask Serious Clot Disorder 52152 2
... plants, human antibodies that could be used to treat ... 2005 American Society for Microbiology Biodefense Research Meeting. , ... is likely to strike at a time and place ... unpredictable nature of such events compels us to develop ...
... before they reach hospital, has the potential to save many ... over a million children die of malaria in Africa. The ... For those who do make it to hospital, half of ... given by injection, is not possible to administer outside hospital, ...
... of breast cancer,patients have an abnormality in a ... along that pathway may be,especially effective for treating ... Texas M. D. Anderson Cancer Center.", , A ... the phosphatidylinositol 3 kinase (PI3K),pathway to breast cancer ...
Other Biology News:Antibodies from plants protect against anthrax 2